Pravastatin

證據等級: L5

預測適應症: 10 個

Pravastatin: From Hypercholesterolaemia to Homozygous Familial Hypercholesterolemia

One-Sentence Summary

Pravastatin is a long-established HMG-CoA reductase inhibitor (statin) used to lower cholesterol and reduce cardiovascular risk. The TxGNN model predicts it may also have a role in Homozygous Familial Hypercholesterolemia (HoFH), with 1 clinical trial and 13 publications currently identified — though, as detailed below, the trial evidence does not directly test pravastatin in this population and the underlying biology limits how much benefit can realistically be expected.

Quick Overview

Item	Content
Original Indication	Hypercholesterolaemia / dyslipidaemia (general statin-class use — no TGA-specific approved wording available in this dataset)
Predicted New Indication	Homozygous Familial Hypercholesterolemia (HoFH)
TxGNN Prediction Score	99.95%
Evidence Level	L3
Australia Market Status	Not Marketed (per this dataset)
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available for pravastatin in this evidence pack. Based on known pharmacology, pravastatin is a member of the HMG-CoA reductase inhibitor (statin) class, and its cholesterol-lowering effect in general hypercholesterolaemia is well established. Mechanistically, statins reduce intracellular cholesterol synthesis, which up-regulates hepatic LDL-receptor expression and increases clearance of LDL cholesterol from the blood — the same pathway implicated in familial hypercholesterolaemia.

However, this mechanism is markedly attenuated in HoFH specifically. Patients with HoFH have little to no functional LDL receptor activity (due to biallelic LDLR, or related PCSK9/APOB, mutations), so the LDL-receptor up-regulation that statins rely on cannot produce a full effect. In clinical practice, statins are used only as adjunctive therapy in HoFH — alongside PCSK9 inhibitors, lomitapide, or LDL apheresis — rather than as a standalone effective treatment. The mechanistic link between pravastatin and HoFH is real, but its expected clinical effect is limited, and this should be clearly flagged to prescribers.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT03510715	Phase 3	Completed	18	Open-label study of alirocumab (not pravastatin) in children/adolescents with HoFH, evaluating LDL-C reduction at 12/24/48 weeks on top of background therapy. Pravastatin is not the study intervention — relevance is limited to population overlap (HoFH paediatric cohort).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31696945	2019	Cochrane Systematic Review	Cochrane Database Syst Rev	Reviews statin use in children with familial hypercholesterolaemia, including homozygous cases; supports short/medium-term safety and LDL-C-lowering efficacy.
28685504	2017	Systematic Review	Cochrane Database Syst Rev	Earlier version of the same Cochrane review on statins in paediatric familial hypercholesterolaemia.
28437620	2017	Guideline (AACE/ACE)	Endocr Pract	US clinical practice guideline for dyslipidaemia management and cardiovascular disease prevention, covering statin therapy across FH severity.
31358055	2019	Mechanistic (iPSC model)	Stem Cell Res Ther	LDL-receptor-deficient hepatocytes derived from iPSCs used to model FH and test CRISPR-based genetic correction — mechanistic, not a pravastatin efficacy study.
34425670	2021	Genetic case study	Iran Biomed J	Identifies a novel LDLRAP1 splice-site variant causing familial hypercholesterolaemia in an affected family; genetics, not treatment.
28416195	2017	RCT (INTREPID)	Lancet HIV	Phase 4 RCT comparing pitavastatin vs pravastatin in HIV-associated dyslipidaemia — direct pravastatin efficacy/safety data, but not in an HoFH population.
15531000	2004	Review	Clin Ther	Review of rosuvastatin, noting HoFH as an approved indication for that agent and comparing lipid-lowering potency across statins including pravastatin.
12269853	2002	Review	Drugs	Review of rosuvastatin showing it outperformed pravastatin, atorvastatin and simvastatin on lipid parameters in hypercholesterolaemic patients.
14727947	2003	Review	Am J Cardiovasc Drugs	Review of ezetimibe as a cholesterol-absorption inhibitor, relevant as a comparator/add-on class in severe hypercholesterolaemia.
9129869	1997	Review	Drugs	Review of atorvastatin pharmacology and efficacy in hyperlipidaemia, used here as a general statin-class comparator.

Three further hits (ezetimibe, atorvastatin general reviews, and PCSK9/CETP background literature) were lower relevance and are omitted for brevity.

Australia Market Information

No ARTG entries are present in this dataset (total_licenses: 0, market_status: 未上市). No product name, dosage form, or approved indication text could be extracted. This does not necessarily reflect pravastatin’s true Australian market status generally — it reflects a gap in the data source queried for this evidence pack and should be verified directly against the ARTG before any decision is finalised.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. No key warnings, contraindications, or drug interaction data were retrievable in this evidence pack (DDI query status: not found).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic rationale for pravastatin in HoFH is biologically plausible but inherently limited — HoFH patients have minimal functional LDL receptor activity, so statins can only ever be adjunctive, not primary, therapy. No trial or publication in this evidence pack directly tests pravastatin’s efficacy in HoFH; the strongest evidence (Cochrane reviews, AACE/ACE guideline) supports statins as a drug class in paediatric FH generally, not pravastatin specifically in the homozygous form.

To proceed, the following is needed:

TFDA/TGA-equivalent Product Information (warnings, contraindications) — currently a blocking data gap preventing any safety pre-assessment (DG001)
Confirmed mechanism of action data for pravastatin (DG002)
Verification of actual ARTG listing status, as the “not marketed” flag in this dataset conflicts with pravastatin’s well-known long-standing generic availability and should be checked directly
A treatment-positioning statement clarifying that pravastatin would only be considered as an adjunct to PCSK9 inhibitors, lomitapide, or LDL apheresis in HoFH, not as monotherapy
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.